Overview

Alprostadil in Maculopathy Study (AIMS)

Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Evaluation of efficacy of alprostadil (prostaglandin E1) for treatment of patients suffering from dry age-related macula degeneration
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Alprostadil